Harmony Biosciences Holdings (HRMY) Work In Process (2023 - 2024)

Harmony Biosciences Holdings' (HRMY) quarterly Work In Process came in at $3.5 million in Q4 2024, up 72.72% year-on-year from $2.0 million in Q1 2024, and up 36.88% quarter-over-quarter from $2.5 million in Q3 2024.

Harmony Biosciences Holdings (HRMY) Work In Process (2023 - 2024) Analysis & Trends

Harmony Biosciences Holdings has disclosed Work In Process across 2 years of filings, most recently posting $3.5 million for Q4 2024.

  • Work In Process for Q4 2024 came in at $3.5 million, up 72.72% year-over-year; the trailing twelve-month figure through Dec 2024 was $3.5 million (up 72.72% YoY), and the FY2024 annual result was $3.5 million, up 72.72% from the prior year.
  • Work In Process came in at $3.5 million for Q4 2024 at Harmony Biosciences Holdings, up from $2.5 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $3.5 million in Q4 2024 to a low of $1.7 million in Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Harmony Biosciences Holdings 1.92 Bn 1.28 Bn 170.88 Mn

Historic Data

Download Data
DateValue
Dec 31, 2024 3.49 Mn
Sep 30, 2024 2.55 Mn
Jun 30, 2024 1.74 Mn
Mar 31, 2024 1.75 Mn
Dec 31, 2023 2.02 Mn